Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Penang, Malaysia
Short Communication
Role/Risks of Proton Pump Inhibitors and Infliximab in IBD Patients
Author(s): Lim Vuanghao*
Proton Pump Inhibitors (PPIs) are the most generally endorsed class of medicine for the treatment of indigestion and corrosive related issues. They work by obstructing
the site of corrosive creation in the parietal cell of the stomach. Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune
diseases mainly Ulcerative Colitis (UC) and Crohn's Disease (CD). Infliximab targets TNF, thought to be more related to Th1 cytokines... Read More»
DOI:
10.37421/2476-1958.2020.5.134
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 